Here is a brief preview of this blast: In our previous six-part series, the Celltelligence team discussed the pipeline, manufacturing technology, novel platforms, and potential strategy to maintain an innovative clinical program for Novartis, BMS, and Gilead (Kite):
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.